Xifaxan Tablet
Product Images NDC 65649-303

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 65649-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Salix Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

200mg Label

The packaging label for Xifaxan (rifaximin) tablets, 200 mg, shows a prescription drug bottle label with orange background and circular design. It contains 30 tablets and is labeled for oral use. The labeler is Salix Pharmaceuticals, Inc. The NDC number 65649-301-03 is visible along with storage and dispensing instructions.*

FDA Label Image

550mg Label

Xifaxan (rifaximin) 550 mg tablets label from Salix Pharmaceuticals, Inc. The label shows the product name, strength, dosage form, and quantity of 60 tablets. It includes the NDC number 65649-303-02 and information for dispensing, storage, and manufacturer details. The label also displays the Salix logo and specifies Rx only status.*

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of rifaximin, the active ingredient in XIFAXAN tablets. The diagram illustrates the molecular structure showing various atomic bonds and functional groups.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier survival curve showing the proportion of patients without breakthrough hepatic encephalopathy (HE) over days post-randomization comparing XIFAXAN treatment to placebo. The graph depicts higher survival without breakthrough HE for XIFAXAN versus placebo, with statistical values including hazard ratio 0.421, 95% confidence interval 0.276 to 0.641, and a log-rank p-value less than 0.0001.*

FDA Label Image

Figure 2 (Image 03)

A Kaplan-Meier curve chart displaying the proportion of patients without hepatic encephalopathy (HE)-related hospitalization over days post-randomization. The chart compares two groups labeled XIFAXAN and Placebo, showing a higher proportion without hospitalization in the XIFAXAN group over time. A hazard ratio with confidence interval and p-value is included in the inset.*

FDA Label Image

Figure-3 (Image 04)

A clinical trial flowchart illustrating treatment phases for XIFAXAN (rifaximin). It details a screening phase, treatment phases 2 to 4, maintenance phases, randomization, and follow-up periods over several weeks, including placebo and rifaximin (RFX) administration. The diagram highlights evaluation periods, follow-up durations, and notes symptom diary collection throughout.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.